NCT01999920View on ClinicalTrials.gov

Vilazodone for Separation Anxiety Disorder

PHASE4CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

December 31, 2013

Primary Completion Date

March 31, 2017

Study Completion Date

December 30, 2017

Conditions
Separation Anxiety Disorder
Interventions
DRUG

Vilazodone

10mg to 40mg per day for 12 weeks

DRUG

Placebo

One to two pills per day for 12 weeks

Trial Locations (1)

10032

New York State Psychiatric Institute, New York

Sponsors

Collaborators (1)

Forest Laboratories
All Listed Sponsors
collaborator

Forest Laboratories

INDUSTRY

lead

New York State Psychiatric Institute

OTHER

NCT01999920 - Vilazodone for Separation Anxiety Disorder | Biotech Hunter | Biotech Hunter